Cellectar Biosciences, Inc. (CLRB): debt financing — Cellectar Biosciences amends NJ office lease through 2029, aggregate rent ~$918K

Cellectar Biosciences, Inc.

Amended lease for 3,983 sq ft at 100 Campus Drive, Florham Park, NJ from March 1, 2023 to April 30, 2029.
Security deposit reduced from $75,000 to $23,566 under amended terms.
Aggregate rent approx. $918,000, reduced to ~$893,000 after rent abatements.
Company has option to extend term for one additional 60-month period.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Cellectar Biosciences, Inc. amended lease obligation of approximately $918,000 with CAMPUS 100 LLC maturing April 30, 2029.

Instrument: lease obligation
Principal: approximately $918,000
Counterparty: CAMPUS 100 LLC
Maturity: April 30, 2029
Event: amendment

Exact text from the filing

ntered into an Amended Agreement of Lease (the “Amended Lease”), with CAMPUS 100 LLC (the “Landlord”). Under the Amended Lease, the Company will continue to lease

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cellectar Biosciences, Inc. amended Amended Agreement of Lease with CAMPUS 100 LLC (the "Landlord") valued at approximately $918,000 (effective 2022-12-30).

Action: amendment
Agreement: lease
Counterparty: CAMPUS 100 LLC (the "Landlord")
Value: approximately $918,000
Effective: 2022-12-30

Exact text from the filing

On December 30, 2022, Cellectar Biosciences, Inc. (the “Company”) entered into an Amended Agreement of Lease (the “Amended Lease”), with CAMPUS 100 LLC (the “Landlord”).

View on SEC.gov

102 debt financings filed in the last 30 days. Browse all debt financings →

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-000616

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.